

9 January 2019

RESPIRI



## RESPIRI EXHIBITS AT CES, THE WORLD'S LARGEST TECHNOLOGY SHOW

**Respiri Limited (ASX:RSH)** today announced the company's exhibit for wheezo™ has opened at the Consumer Electronics Show, CES 2019, as part of the digital health showcase in Las Vegas, USA. Along with the world's biggest tech companies, Respiri is one of more than 4,500 exhibiting companies at the conference that has attracted more than 180k attendees from 150 countries and 6,500 media.

Digital Health and the role of technology in advancing patient self-management is evolving faster than any other area of tech innovation and as such, the health and wellness segment is well represented at CES. Respiri is in attendance to understand the competitive landscape, the company's positioning in the marketplace and to create brand awareness ahead of the launch of wheezo™ in 2019. Based on the current timeline, we expect to launch in US in 12 - 18 months, once we have FDA clearance. CES, which attracts significant media attention, will be a key meeting and platform to support the US launch at that time.

Speaking from Las Vegas early this morning, CEO, Mario Gattino said, "CES is a spectacle; it's simply huge and we're fortunate to have secured a booth at what really is a must-attend event for companies like us. The giants in consumer health and wellness are here, alongside new technology innovators and cutting edge companies, but no one is even close to providing a solution for asthma management like Respiri. We still have first-mover advantage. When I take people through the breath sensor and app demo, and explain the functionality and promise for patients, reaction is incredibly positive and it is universally agreed that wheezo™ is a game changer."

CES concludes on Friday, 11 January 2019.

--END--



**CES 2019**

Jan. 8-11  
Las Vegas, NV

CEO, Mario Gattino, Booth: Sands, Halls A-D - 43842  
Health & Wellness

Contact:  
Wani Wall  
CXO  
+61 3 9653 9160

## **About Respi Limited**

Respi's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respi's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respi Limited's operations are based in Melbourne, Australia.

## **Forward Looking Statements**

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.